68Ga-PSMA-11在唾液腺中的非PSMA相关摄取机制的首个临床病理证据
本研究通过放射自显影和免疫组化分析9例患者下颌下腺、4例胰腺组织和9例前列腺癌组织的PSMA表达,并对比60例68Ga-PSMA-11 PET的SUVmax。结果显示下颌下腺PSMA表达极低但PET摄取高,提示唾液腺高摄取并非主要依赖PSMA介导。
要点
- 下颌下腺PSMA表达局限于闰管,免疫组化评分10-15,放射自显影信号仅1.3%±0.9%。
- 下颌下腺68Ga-PSMA-11 PET的SUVmax高达23.5±5.2,与低PSMA表达不匹配。
- 前列腺癌组织中PSMA表达与PET SUVmax显著相关(P<0.001,R2=0.897)。
核心结论
- PSMA放射性配体在唾液腺的高积累并非主要由于PSMA介导的摄取。
研究设计与样本
- 分析9例患者下颌下腺、4例胰腺组织和9例前列腺癌组织,采用PSMA免疫组化(IRS评分)和177Lu-PSMA-617放射自显影。
- 在60例复发疾病临床68Ga-PSMA-11 PET扫描中量化唾液腺、胰腺和前列腺癌组织的SUVmax。
主要发现
- 前列腺癌组织免疫组化IRS为70-300,放射自显影为标准的1.3%-22%,PET SUVmax为4.4-16,放射自显影与SUVmax显著相关(P<0.001,R2=0.897)。
- 胰腺组织免疫组化IRS=0,放射自显影0.1%±0.05%,PET SUVmax 3.1±1.1。
- 下颌下腺免疫组化IRS=10-15,放射自显影1.3%±0.9%,但PET SUVmax 23.5±5.2。
关键数值与推荐
- 前列腺癌组织免疫组化IRS范围70-300,放射自显影信号为标准的1.3%-22%,PET SUVmax范围4.4-16。
- 胰腺组织免疫组化IRS=0,放射自显影0.1%±0.05%,PET SUVmax 3.1±1.1。
- 下颌下腺免疫组化IRS=10-15,放射自显影1.3%±0.9%,PET SUVmax 23.5±5.2。
临床怎么用
- 使用PSMA放射性配体治疗时,应关注唾液腺辐射损伤风险,因其摄取机制可能非PSMA介导。
- 解读68Ga-PSMA-11 PET唾液腺高摄取时,不应简单归因于PSMA表达水平。
局限性
- 样本量较小(下颌下腺9例、胰腺4例、前列腺癌9例)。
- 放射自显影使用177Lu-PSMA-617,PET使用68Ga-PSMA-11,示踪剂不同可能影响可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The intense accumulation of prostate-specific membrane antigen (PSMA) radioligands in salivary glands is still not well understood. It is of concern for therapeutic applications of PSMA radioligands, because therapeutic radiation will damage these glands. A better understanding of the uptake mechanism is, therefore, crucial to find solutions to reduce toxicity. The aim of this study was to investigate whether the accumulation of PSMA-targeting radioligands in submandibular glands (SMGs) can be explained with PSMA expression levels using autoradiography (ARG) and immunohistochemistry (IHC). Methods: All patients gave written informed consent for further utility of the biologic material. The SMG of 9 patients, pancreatic tissue of 4 patients, and prostate cancer (PCA) lesions of 9 patients were analyzed. Tissue specimens were analyzed by means of PSMA-IHC (using an anti-PSMA-antibody and an immunoreactivity score system [IRS]) and ARG using 177Lu-PSMA-617 (with quantification of the relative signal intensity compared with a PSMA-positive standard). The SUVmax in salivary glands, pancreas, and PCA tissues were quantified in 60 clinical 68Ga-PSMA-11 PET scans for recurrent disease as well as the 9 primary tumors selected for ARG and IHC. Results: PCA tissue samples revealed a wide range of PSMA staining intensity on IHC (IRS = 70-300) as well as in ARG (1.3%-22% of standard). This variability on PCA tissue could also be observed in 68Ga-PSMA-11 PET (SUVmax, 4.4-16) with a significant correlation between ARG and SUVmax (P < 0.001, R2 = 0.897). On IHC, ARG, and 68Ga-PSMA-11 PET, the pancreatic tissue was negative (IRS = 0, ARG = 0.1% ± 0.05%, SUVmax of 3.1 ± 1.1). The SMG tissue displayed only focal expression of PSMA limited to the intercalated ducts on IHC (IRS = 10-15) and a minimal signal on ARG (1.3% ± 0.9%). In contrast, all SMG showed a high 68Ga-PSMA-11 accumulation on PET scans (SUVmax 23.5 ± 5.2). Conclusion: Our results indicate that the high accumulation of PSMA radioligands in salivary glands does not correspond to high PSMA expression levels determined using ARG and IHC. These findings provide evidence, that the significant accumulation of PSMA radioligands in SMG is not primarily a result of PSMA-mediated uptake.
引用
- Rupp NJ, Umbricht CA, Pizzuto DA, et al. First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands. J Nucl Med. 2019. PMID: 30737300. doi:10.2967/jnumed.118.222307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。